Terms: = Colorectal cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Treatment
112 results:
1. Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Flecchia C; Auclin E; Alouani E; Mercier M; Hollebecque A; Turpin A; Mazard T; Pernot S; Dutherage M; Cohen R; Borg C; Hautefeuille V; Sclafani F; Ben-Abdelghani M; Aparicio T; De La Fouchardière C; Herve C; Perkins G; Heinrich K; Kunzmann V; Gallois C; Guimbaud R; Tougeron D; Taieb J
Br J Cancer; 2024 Feb; 130(3):442-449. PubMed ID: 38102227
[TBL] [Abstract] [Full Text] [Related]
2. Clinical, Functional, and Nutritional Efficacy of a Glutamine-Enriched Oligomeric Diet in Patients with Rectal cancer.
Peña Vivas JDC; Orduz Arena AC; Alonso García A; Carrascal Gordillo CF; Martínez Gutiérrez R; Rodríguez-Acosta Caballero C; Fernández Freije I; Paino Martínez AB; Belloso Cuesta T; Juan Rijo G; Calleja Fernández A
Nutr Cancer; 2024; 76(1):128-136. PubMed ID: 37994411
[TBL] [Abstract] [Full Text] [Related]
3. Real-World treatment Sequencing in Vulnerable Patients with Metastatic colorectal cancer: A Multicenter Retrospective Study.
Mitani S; Kito Y; Hino K; Kawakami K; Izawa N; Hanamura F; Yamamoto Y; Shoji H; Komori A; Boku S; Tsuchihashi K; Kato K; Nonagase Y; Matsumoto T; Furuta M; Kawakami H
Target Oncol; 2023 Sep; 18(5):707-715. PubMed ID: 37668815
[TBL] [Abstract] [Full Text] [Related]
4. Changes in Prescribing Patterns in Stage III Colon cancer.
Ou FS; Walden DJ; Larson JJ; Kang S; Griswold CR; Ueberroth BE; Patel B; Draper A; Raman P; Alese OB; Sonbol MB; Bekaii-Saab TS; Wu CS; Ahn DH
J Natl Compr Canc Netw; 2023 Aug; 21(8):841-850.e4. PubMed ID: 37549913
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
Huang F; Yang H; Bao W; Bin Y; Zhou S; Wang M; Lv X
Clin Transl Oncol; 2024 Feb; 26(2):468-476. PubMed ID: 37414979
[TBL] [Abstract] [Full Text] [Related]
6. treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
Liang YH; Chen KH; Shao YY
Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
[TBL] [Abstract] [Full Text] [Related]
7. The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival.
Aoyama T; Oba K; Honda M; Muto M; Mayanagi S; Maeda H; Kanda M; Kashiwabara K; Sakamoto J; Yoshikawa T
Int J Clin Oncol; 2023 Jun; 28(6):777-784. PubMed ID: 37039949
[TBL] [Abstract] [Full Text] [Related]
8. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
[TBL] [Abstract] [Full Text] [Related]
9. Utility of combined gadoxetic acid and ferumoxytol-enhanced liver MRI for preoperative detection of colorectal cancer liver metastases: a pilot study.
Carney BW; Gholami S; Fananapazir G; Sekhon S; Lamba R; Loehfelm TW; Wilson MD; Corwin MT
Acta Radiol; 2023 Apr; 64(4):1357-1362. PubMed ID: 36437569
[TBL] [Abstract] [Full Text] [Related]
10. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study.
Yekedüz E; Özbay MF; Çağlayan D; Yıldırım A; Erol C; Yıldırım HÇ; Tunç S; Özyurt N; Özdemir F; Şendur MAN; Işıkdoğan A; Kılıçkap S; Ürün Y; Yalçın Ş; Artaç M; Coşkun HŞ; Utkan G
Eur J Clin Pharmacol; 2022 Dec; 78(12):1973-1979. PubMed ID: 36266366
[TBL] [Abstract] [Full Text] [Related]
11. Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
Matsuoka H; Yamada T; Ohta R; Yoshida Y; Watanabe T; Takahashi M; Kosugi C; Fukazawa A; Kuramochi H; Matsuda A; Sonoda H; Yoshida H; Hasegawa S; Sakamoto K; Otsuka T; Hirata K; Koda K;
Int J Clin Oncol; 2022 Dec; 27(12):1859-1866. PubMed ID: 36201089
[TBL] [Abstract] [Full Text] [Related]
12. Diabetes Mellitus and Other Predictors for the Successful treatment of Metastatic colorectal cancer: A Retrospective Study.
Roman D; Saftescu S; Timar B; Avram V; Braha A; Negru Ș; Bercea A; Serbulescu M; Popovici D; Timar R
Medicina (Kaunas); 2022 Jun; 58(7):. PubMed ID: 35888591
[TBL] [Abstract] [Full Text] [Related]
13. Necessity of external iliac lymph nodes and inguinal nodes radiation in rectal cancer with anal canal involvement.
Zheng R; Zhang Y; Chen R; Guan B; Lin Y; Wang B; Li X; Chi P; Chen X; Xu B
BMC Cancer; 2022 Jun; 22(1):657. PubMed ID: 35701738
[TBL] [Abstract] [Full Text] [Related]
14. Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study.
Neuhann TM; Haub K; Steinke-Lange V; Morak M; Laner A; Locher M; Holinski-Feder E
Fam Cancer; 2022 Oct; 21(4):463-472. PubMed ID: 35570229
[TBL] [Abstract] [Full Text] [Related]
15. Quality of Life and Survival of Metastatic colorectal cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
Hamers PAH; Vink GR; Elferink MAG; Stellato RK; Dijksterhuis WPM; Punt CJA; Koopman M; May AM;
Clin Colorectal Cancer; 2022 Jun; 21(2):154-166. PubMed ID: 35474007
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic colorectal cancer-An Observational Cohort Study in the Real World.
Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
[TBL] [Abstract] [Full Text] [Related]
17. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Élez E; Gómez-España MA; Grávalos C; García-Alfonso P; Ortiz-Morales MJ; Losa F; Díaz IA; Graña B; Toledano-Fonseca M; Valladares-Ayerbes M; Polo E; Salgado M; Martínez de Castro E; Safont MJ; Salud A; Ruiz-Casado A; Tabernero J; Riesco MDC; Rodriguez-Ariza A; Aranda E
Br J Cancer; 2022 Apr; 126(6):874-880. PubMed ID: 34937947
[TBL] [Abstract] [Full Text] [Related]
18. Tailored Strategy for Locally Advanced Rectal Carcinoma (GRECCAR 4): Long-term Results From a Multicenter, Randomized, Open-Label, Phase II Trial.
Rouanet P; Rullier E; Lelong B; Maingon P; Tuech JJ; Pezet D; Castan F; Nougaret S;
Dis Colon Rectum; 2022 Aug; 65(8):986-995. PubMed ID: 34759247
[TBL] [Abstract] [Full Text] [Related]
19. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
Dumbrava EE; Call SG; Huang HJ; Stuckett AL; Madwani K; Adat A; Hong DS; Piha-Paul SA; Subbiah V; Karp DD; Fu S; Naing A; Tsimberidou AM; Moulder SL; Koenig KH; Barcenas CH; Kee BK; Fogelman DR; Kopetz ES; Meric-Bernstam F; Janku F
ESMO Open; 2021 Oct; 6(5):100230. PubMed ID: 34479035
[TBL] [Abstract] [Full Text] [Related]
20. Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).
Kosugi C; Koda K; Denda T; Ishibashi K; Ishida H; Seike K; Sakata H; Yanagisawa S; Miyazaki A; Takayama W; Koike N; Shimizu H; Matsubara H
Int J Colorectal Dis; 2021 Dec; 36(12):2637-2647. PubMed ID: 34368890
[TBL] [Abstract] [Full Text] [Related]
[Next]
